Fertility-sparing treatment of endometrial cancer: options, outcomes and pitfalls by Kesterson, Joshua P. & Fanning, James
INTRODUCTION
Endometrial	cancer	is	the	most	common	gynecologic	ma-
lignancy	in	the	United	States,	with	over	40,000	cases	diag-
nosed	each	year	[1].	While	a	majority	of	cases	are	diagnosed	
in	post-menopausal	women,	up	to	14%	of	cases	will	be	in	
pre-menopausal	women,	including	4%	diagnosed	in	women	
less	than	40	years	of	age	[2-5].	A	majority	of	cases	in	younger	
women	are	early	stage	and	low	grade,	thus	associated	with	an	
excellent	outcome	[2].	While	hysterectomy,	bilateral	salpingo-
oophorectomy	and	assessment	of	the	retroperitoneal	lymph	
nodes	is	standard	initial	treatment	for	endometrial	cancer,	
younger	women	may	desire	fertility	sparing	options.	The	
decision	to	proceed	with	conservative	management	in	this	
younger	patient	population	is	associated	with	multiple	com-
plexities,	including	the	inherent	oncologic	risks	of	an	inad-
equately	staged	and	treated	endometrial	cancer,	the	risk	of	a	
synchronous	or	meta-synchronous	cancer,	the	increased	risk	
of	an	inherited	genetic	predisposition	to	malignancy	and	the	
lack	of	uniformity	in	the	medical	management	and	surveil-
lance.	In	this	review	we	will	discuss	the	conservative	manage-
ment	of	endometrial	cancer,	specifically	the	role	of	progestin	
hormonal	therapy,	including	the	risks	associated	with	non-
standard	care,	appropriate	candidate	selection	and	work	up,	
expected	outcomes,	various	progestin	agents	and	recom-
mended	follow-up.
WHAT ARE THE ONCOLOGIC RISKS?
While	most	young	women	with	endometrial	cancer	have	
low	grade	tumors	confined	to	the	uterus	[2],	any	decision	to	
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deviate	from	the	standard	approach	of	hysterectomy	with	
oophorectomy	and	staging	should	be	done	so	with	the	ac-
knowledgement	of	the	risk	of	an	undiagnosed,	and	therefore	
subsequently	untreated,	synchronous	or	metastatic	cancer.	In	
Duska	et	al’s	review	[2]	of	women	less	than	40	years	of	age,	a	
majority	of	women	had	stage	I	and	grade	I	disease,	however	
19	of	95	patients	(20%)	had	disease	beyond	the	uterus,	includ-
ing	10	with	advanced	disease.	Four	women	died	as	a	result	
of	their	disease.	In	a	study	from	Australia	of	premenopausal	
women	with	endometrial	cancer,	there	was	a	higher	inci-
dence	of	coexistent	ovarian	malignancies	when	compared	to	
women	greater	than	45	years	old	[3].	Five	of	17	women	less	
than	45	had	stage	III	or	IV	disease.	In	a	review	of	over	2,000	
women	aged	40	years	or	younger	collected	from	the	National	
Cancer	Institute	database,	although	a	majority	of	patients	had	
disease	confined	to	the	uterus	(75%),	approximately	17%	had	
stage	III	or	IV	disease	[4].	These	younger	patients	are	also	at	in-
creased	risk	of	other	gynecologic	pathologies,	including	ovar-
ian	tumors.	In	a	review	of	young	women	with	endometrial	
cancer	by	Walsh	et	al.	[6],	26	of	102	women	(25%)	were	found	
to	have	coexisting	epithelial	ovarian	tumors	(23	synchronous	
primaries	and	3	metastases).	These	studies	confirm	the	need	
for	thorough	examination	and	careful	patient	selection,	while	
highlighting	the	risks	inherent	in	conservative	management	
of	an	unstaged	cancer.	
The	pathogenesis	of	endometrial	cancer	in	a	young	woman	
is	usually	a	resultant	of	a	hyperestrogenic	state	that	arises	in	
the	setting	of	endometrial	hyperplasia.	A	tissue	biopsy	con-
sistent	with	endometrial	hyperplasia	should	be	considered	a	
potential	harbinger	of	endometrial	cancer.	This	relation	was	
initially	definitively	established	in	the	seminal	paper	by	Kur-
man	et	al.	[7]	in	which	they	reported	a	29%	risk	of	progression	
of	endometrial	hyperplasia	with	atypia	to	endometrial	cancer.	
More	recently,	Trimble	al.	[8]	reported	a	43%	incidence	of	en-
dometrial	cancer	in	patients	with	a	preoperative	diagnosis	of	
atypical	endometrial	hyperplasia.	This	high	rate	of	concurrent	
carcinoma	warrants	consideration	in	management	decisions.
WHO ARE APPROPRIATE CANDIDATES? 
Considering	that	a	majority	of	women	with	endometrial	
cancer	have	early	stage	disease	which	will	be	cured	with	
surgery	alone,	every	effort	should	be	taken	to	ensure	that	
the	endometrial	cancer	is	confined	to	the	endometrium	and	
low	grade,	therefore	likely	to	respond	to	hormonal	therapy	
without	compromising	their	ultimate	curability.	Pretreatment	
evaluation	should	consist	of	a	full	evaluation	including	a	com-
plete	history	and	physical	with	attention	toward	and	signs	or	
symptoms	suspicious	for	advanced/metastatic	disease.	If	not	
already	done,	a	dilation	and	endometrial	curettage	should	
be	performed,	as	it	has	been	shown	to	be	more	accurate	in	
correlating	with	final	pathology	in	grade	I	endometrial	cancer	
when	compared	to	office	endometrial	biopsy	[9].	Additionally,	
the	endometrial	cancer	is	more	likely	to	be	removed	with	a	
D&C	than	an	endometrial	biopsy	[10].
After	confirming	the	low	grade	nature	of	the	tumor,	at-
tempts	should	then	be	undertaken	to	rule	out	myometrial	
invasion	and	lymph	node	metastasis.	MRI	has	proven	to	be	a	
superior	means	to	determine	myometrial	invasion	when	com-
pared	to	transvaginal	ultrasound	and	CT.	When	comparing	
histologic	findings	to	MRI,	Sironi	et	al.	[11]	reported	a	sensitiv-
ity	and	specificity	of	74%	for	assessing	superficial	myometrial	
invasion.	The	sensitivity	and	specificity	for	tumor	confined	to	
the	endometrium	was	57%	and	96%,	respectively.	In	a	similar	
study,	the	reported	accuracy	of	detecting	deep	myometrial	
invasion	and	cervical	invasion	was	95%	and	88%,	respectively	
[12].	MRI	can	also	be	used	to	assess	loco-regional	disease	
spread	[13].	Enlarged	lymph	nodes	and	those	with	central	ne-
crosis	should	be	considered	suspicious	for	metastatic	disease.	
WHAT PERCENTAGE OF PATIENTS WILL RESPOND TO  
HORMO  NAL THERAPY?
A	majority	of	patients	with	well	differentiated	endometrial	
cancer	respond	to	treatment	with	progestational	agents.	In	
a	meta-analysis	of	27	articles,	including	81	patients,	Ramirez	
et	al.	[14]	reported	that	76%	of	patients	responded	to	treat-
ment.	Twenty-four	percent	of	patients	who	initially	responded	
ultimately	recurred	at	a	median	of	19	months.	Consideration	
must	be	given	to	the	publication	bias	inherent	in	the	studies	
analyzed,	whereby	studies	of	successful	treatment	are	more	
likely	to	be	reported	and	published,	thus	overestimating	the	
success	rate.	In	the	only	prospective	trial,	55%	of	cases	of	en-
dometrial	cancer	were	successfully	treated	with	MPA	[15].
WHAT HORMONAL THERAPY TO USE?
The	initial	data	regarding	hormonal	therapy	for	endometrial	
hyperplasia	and	cancer	was	from	small	case	series	and	retro-
spective	reports.	For	this	reason	there	is	no	consensus	regard-
ing	the	ideal	progestin	agent.	In	a	review	of	available	studies,	
the	most	commonly	used	agents	were	modroxyprogesterone	
acetate	(MPA;	44%)	and	megesterol	acetate	(35%)	[14].	In	the	
first	multicenter	prospective	trial	of	fertility-sparing	treatment	
with	progestins,	investigators	from	Japan	used	a	MPA	600	mg	Joshua P. Kesterson, et al.
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oral	dose	given	daily	[15].	Additionally,	other	small	series	have	
reported	treatment	with	levonorgestrel	intrauterine	devices	
(IUD)	[16],	in	addition	to	hysteroscopic	resection	[17]	and	me-
droxyprogesterone	[18].
The	choice	of	progestin	and	its	method	of	delivery	should	
be	dictated	by	its	expected	efficacy	as	well	as	expected	side	
effects	and	patient	tolerability.	Orally	administered	progestins	
are	not	without	side-effects,	including	thrombus	formation,	
mood	alterations,	headaches,	weight	gain	and	breast	pain	
and/or	tenderness.	In	their	prospective	trial	using	600	mg	
MPA,	Ushijima	et	al.	[15]	reported	the	most	common	side	ef-
fects	were	weight	gain	and	liver	dysfunction.	There	were	no	
cases	of	thromboembolism.	Progesterone	therapy	is	contra-
indicated	in	those	with	a	thromboembolism	history,	breast	
cancer	or	hepatic	dysfunction.	The	progesterone-releasing	
IUD	is	a	means	to	generate	a	localized	effect	within	the	en-
dometrium	while	avoiding	the	adverse	systemic	toxicity.	The	
levonorgestrel-releasing	intrauterine	system	(Mirena)	releases	
20	mcg	of	levonorgestrel	per	day	[19].
WHAT IS THE APPROPRIATE SURVEILLANCE OF THESE 
PATIENTS?
The	importance	of	close	surveillance	cannot	be	overempha-
sized	as	the	consequences	of	the	lack	of	recognition	of	a	non-
hormonally	responsive	endometrial	cancer	could	ultimately	
prove	fatal.	Although	a	majority	of	these	carefully	selected	
patients	will	respond	to	progestin	therapy,	there	is	no	way	
to	accurately	predict	who	will	be	a	responder	versus	a	non-
responder.	A	thinning	of	the	endometrium	as	seen	on	trans-
vaginal	ultrasound	is	associated	with	an	increased	chance	of	
responding	to	progestin	therapy	[15].	However,	the	predictive	
value	is	not	sufficient	enough	to	obviate	endometrial	sam-
pling.	BMI	and	polycystic	ovarian	syndrome	also	do	not	pre-
dict	likelihood	of	response.	
Among	patients	who	do	respond,	a	majority	will	do	so	by	
16	weeks	[15].	We	would	recommend	that	assessment	of	re-
sponse	should	be	in	the	form	of	endometrial	sampling	at	four	
to	six	months	after	initiating	progestin	therapy.	Those	with	
persistence	or	progression	of	the	endometrial	cancer	should	
be	counseled	to	pursue	more	definitive	therapy	as	those	
who	have	not	responded	by	at	16	weeks	are	unlikely	to	do	
so.	Those	who	have	a	documented	histologic	response	and	
wish	to	pursue	childbearing	should	follow-up	with	a	repro-
ductive	endocrinologist	with	due	haste.	Responders	who	do	
not	wish	to	pursue	fertility	immediately	should	be	continued	
on	hormonal	therapy.	The	duration	with	which	the	hormonal	
therapy	will	be	successful	is	unknown.	Even	initial	responders	
are	at	risk	of	recurrence,	including	extrauterine	disease	[20-22].
WHAT ARE THE EXPECTED REPRODUCTIVE OUTCOMES?
It	is	impossible	to	calculate	the	rate	of	successful	concep-
tions	as	the	denominator	of	the	number	of	women	pursuing	
fertility	is	unknown.	Most	patients	who	do	conceive	after	con-
servative	therapy	require	assisted	reproductive	technologies,	
including	in	vitro	fertilization	[15,23-25].	These	patients	face	
difficulty	conceiving	secondary	to	obesity,	polycystic	ovarian	
syndrome	and	chronic	anovulation.	Secondary	to	these	issues	
we	recommend	an	initial	consultation	with	a	reproductive	en-
docrinologist	in	order	to	assess	the	patient’s	reproductive	op-
tions	and	likelihood	of	conception.	This	ensures	appropriately	
informed	expectations	regarding	reproductive	potential	and	
thus	the	patient’s	desire	to	proceed	with	fertility-preserving	
therapy.
WHAT ADDITIONAL COUNSELING SHOULD THESE WOMEN 
RECEIVE?
In	addition	to	an	extensive	conversation	regarding	the	non-
standard	nature	of	progestin	therapy	for	endometrial	cancer	
and	the	risks	intrinsic	to	an	unstaged	cancer,	these	women	
warrant	additional	counseling.	As	young	women	with	endo-
metrial	cancer	are	often	obese,	they	should	be	encouraged	
to	institute	dietary	and	healthy	lifestyle	modifications,	includ-
ing	exercise,	with	subsequent	referrals	made	to	ensure	their	
implementation.	Additionally	it	should	be	appreciated	that	
women	diagnosed	with	endometrial	cancer	at	a	young	age	
are	at	increased	risk	for	a	mismatch	repair	gene	mutation	as-
sociated	with	Lynch	syndrome	and	should	be	referred	for	
genetic	counseling	[26].	Identification	of	those	with	this	inher-
ited	genetic	predisposition	will	allow	the	patient	and	her	rela-
tives	to	undertake	additional	cancer	prevention	strategies.
CONCLUSION
The	care	of	the	premenopausal	endometrial	cancer	patient	
desirous	of	maintaining	her	reproductive	potential	poses	
several	challenges.	While	hormonal	therapy	with	progestin	
agents	are	effective	in	a	majority	of	treated	cases,	it	is	not	
without	risks.	Risks	include	an	unrecognized	and	untreated	
advanced	endometrial	cancer	or	synchronous	tumor.	Patients	
should	be	carefully	selected	and	extensively	counseled	re-
garding	the	deviation	from	the	standard	of	care,	the	oncologic	Fertility-sparing treatment of endometrial cancer
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risks,	and	the	subsequent	likely	need	for	reproductive	technol-
ogies	to	ensure	conception.	These	young	women	may	harbor	
a	genetic	predisposition	for	endometrial	and	colon	cancer.	
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